Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15566220 | 0.86 | SLC18A3 (0.52) | MCHR1BCHESCN4ADRD2DRD4 | |
| SCHEMBL1282973 | 0.86 | S1PR5 (0.53) | MCHR1SCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL7818044 | 0.84 | SLC6A2 (0.56) | MCHR1 | |
| SCHEMBL10968787 | 0.83 | SLC18A3 (0.54) | MCHR1SCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL10968786 | 0.83 | SLC18A3 (0.54) | MCHR1SCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL10968782 | 0.83 | SLC18A3 (0.54) | MCHR1SCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL21806055 | 0.83 | GAA (0.49) | BCHESCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL1337120 | 0.82 | SIGMAR1 (0.50) | MCHR1SCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL28332659 | 0.82 | SIGMAR1 (0.50) | MCHR1SCN4ADRD2DRD4SIGMAR1 | |
| SCHEMBL24027193 | 0.81 | MCHR1 (0.50) | MCHR1SCN4ADRD2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355115-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-11-18 | — | — | US | disclosed |
| US-20210355115-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-11-18 | — | — | US | disclosed |
| CN-113056455-A | Isoxazole carboxamide compounds and uses thereof | 诺华股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355115-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, ALDH5A1, SLC8B1 | MCHR1 1817/4885BCHE 3178/4885SCN4A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.